Clinical trial · Observational
Can Recurrence of Cancer in the Oropharynx be Detected by Blood Samples?
Specificity and Sensitivity of Circulating HPV-DNA in Patients With Oropharyngeal Squamous Cell Carcinoma
NCT06592716CI-TRIAL-00097421active not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study investigates if longitudinal analyses of cell-free HPV-DNA in blood samples can be utilized to detect recurrence in patients diagnosed and treated for HPV-positive oropharyngeal squamous cell carcinoma.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oropharyngeal Carcinoma | Oropharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Oropharyngeal Squamous Cell Carcinoma (OPSCC) | Oropharyngeal Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.85 |
| Oropharynx Cancer | Malignant Oropharyngeal Neoplasm | ALIAS | 0.90 |
| Oropharynx Cancer, Metastatic | Malignant Oropharyngeal Neoplasm | CURATED_BROADER | 0.78 |
| Oropharynx Cancer, Recurrent | Malignant Oropharyngeal Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Liquid biopsy | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Identify recurrence
- description
- The aim is to identify recurrence through longitudial analyses of circulating tumor HPV-DNA (ctHPV-DNA ) from blood samples.
- interventionNames
- Diagnostic Test: Liquid biopsy
Primary outcomes (1)
- measure
- Sensitivity and specificity of HPV ddPCR
- timeFrame
- At enrollment and at 2 months after end treatment, and hereafter every 6 month for a minimum of 2 years, up to 3 years, or at suspicion of recurrence.
- description
- Sensitivity and specificity of the ddPCR ctHPV-DNA test compared to clinically or radiologically verified recurrence.
Secondary outcomes (5)
- measure
- Time to recurrence by ctHPV-DNA
- timeFrame
- From enrollment and for minimum 2 years, up to 3 years, after treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with newly diagnosed HPV+ (and/or p16+) oropharyngeal squamous cell carcinoma * Above 18 years of age * Informed consent Exclusion Criteria: * The patient does not speak or understand Danish * patients recieving palliative treatment
References
Publications (0)
Data not yet available
No reference posted for this study.